Vanguard Group Inc. Filing Update for Iovance Biotherapeutics Inc.

This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership for Iovance Biotherapeutics Inc. The Vanguard Group, Inc. (Vanguard) has undergone an internal realignment, resulting in the disaggregation of beneficial ownership reporting for certain subsidiaries and business divisions. As a result, Vanguard no longer reports beneficial ownership of securities held by these entities. The filing states that Vanguard, including its managed accounts, retains the right to receive or direct the receipt of dividends and proceeds from the sale of the reported securities. No single other person holds more than a 5% interest in the securities. The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer. The previous value of holdings was $74,275,326.0, with 27,207,079 shares held. The current filing reports 0 shares and 0.0% ownership, with 0.0 value change. This filing is an amendment no. 6.